Salient Capital Advisors’s AbbVie ABBV Stock Holding History

Salient Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10,590	Closed	-$768K	–	60
2017 Q2	$768K	Buy	10,590 +30	+0.3%	+$2.02K	0.02%	131
2017 Q1	$688K	Sell	10,560 -3,175	-23%	-$200K	0.01%	157
2016 Q4	$860K	Sell	13,735 -513	-4%	-$31.3K	0.02%	132
2016 Q3	$899K	Buy	14,248 +443	+3%	+$28.7K	0.02%	122
2016 Q2	$855K	Sell	13,805 -456	-3%	-$27.8K	0.02%	132
2016 Q1	$815K	Sell	14,261 -10,599	-43%	-$591K	0.02%	134
2015 Q4	$1.47M	Sell	24,860 -19,842	-44%	-$1.14M	0.04%	101
2015 Q3	$2.43M	Sell	44,702 -6,757	-13%	-$440K	0.06%	91
2015 Q2	$3.46M	Sell	51,459 -5,503	-10%	-$359K	0.06%	92
2015 Q1	$3.33M	Sell	56,962 -8,763	-13%	-$529K	0.06%	88
2014 Q4	$4.3M	Sell	65,725 -2,228	-3%	-$140K	0.09%	82
2014 Q3	$3.92M	Buy	67,953 +9,396	+16%	+$522K	0.07%	92
2014 Q2	$3.31M	Sell	58,557 -6,618	-10%	-$347K	0.07%	86
2014 Q1	$3.35M	Buy	65,175 +21,115	+48%	+$1.07M	0.09%	74
2013 Q4	$2.33M	Buy	44,060 +13,095	+42%	+$644K	0.07%	86
2013 Q3	$1.39M	Buy	30,965 +2,051	+7%	+$90.9K	0.06%	92
2013 Q2	$1.2M	Buy	+28,914	New	+$1.26M	0.05%	91

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Salient Capital Advisors's ABBV Position: Q3 2017 in Review

Salient Capital Advisors sold out of AbbVie (ABBV) in Q3 2017, closing a stake of 10,590 shares — an estimated $768K sold.

Salient Capital Advisors first reported a position in ABBV in Q2 2013 and held it in 17 quarters. The position peaked at $4.3M in Q4 2014. 1,798 funds tracked by Wall St. Rank hold ABBV as of Q3 2017.

Salient Capital Advisors reported no remaining AbbVie position as of Q3 2017 after selling out during the quarter.
Salient Capital Advisors sold 10,590 AbbVie shares in Q3 2017, an estimated $768K.
Salient Capital Advisors first reported a position in AbbVie in Q2 2013 and held it in 17 quarters.
Salient Capital Advisors's AbbVie position peaked at $4.3M in Q4 2014.
1,798 funds tracked by Wall St. Rank held AbbVie as of Q3 2017.

Based on Salient Capital Advisors's 13F filing for Q3 2017, filed 6 Nov 2017.